Live
- MVA stunned as MahaYuti heads to landslide win in Maharashtra polls
- Trends in Maha and J'khand a reflection of 'Modi magic': BJP
- Karnataka bypolls: Cong leading, celebrations in Channapatna; BJP concedes defeat in Sandur
- India-EFTA trade pact to drive $100 bn investment, boost 99.6 pc of exports
- Karnataka bypolls: Cong leading in all 3 segments, Kumaraswamy’s son trails by 18,029 votes
- MahaYuti bounces back in Vidarbha after dismal show in Lok Sabha polls
- Priyanka Gandhi will win with huge margin, says Telangana CM Revanth Reddy
- Three paramedics killed in Israeli airstrike on Lebanon
- 321 arrested in Tunisia for drug trafficking, criminal offences
- Bihar bypolls: NDA leading on three seats, BSP on one
Granules India gets tentative nod from FDA for expectorant tablets
Granules India on Thursday said the US health regulator has given its tentative approval to Guaifenesin extended-release tablets used as expectorant.
Hyderabad: Granules India on Thursday said the US health regulator has given its tentative approval to Guaifenesin extended-release tablets used as expectorant.
"US Food & Drug Administration (USFDA) has tentatively approved its Abbreviated New Drug Application for Guaifenesin extended-release tablets, 600 mg and 1200 mg (OTC)," the company said in a filing to the BSE.
Guaifenesin extended-release tablets, 600 mg and 1200 mg are generic equivalent of Mucinex extended-release tablets in the same strengths of RB Health (US) LLC, it added.
Guaifenesin extended-release tablets help loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make cough more productive.
"Being the only vertically integrated generic player for this product, Guaifenesin ER tablets is a nice addition to our growing OTC (Over The Counter) product portfolio in the US market.
"We look forward to bring this product to market upon patent expiry in April 2020," Granules Pharmaceuticals Inc ED Priyanka Chigurupati said.
